Integra LifeSciences Holdings Corp.

How big is Integra LifeSciences Holdings Corp.?

As of Jun 18, Integra LifeSciences Holdings Corp. has a market capitalization of 1,003.73 million, with net sales of 1,624.30 million and a net profit of -28.96 million over the latest four quarters.

Market Cap: As of Jun 18, Integra LifeSciences Holdings Corp. has a market capitalization of 1,003.73 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Integra LifeSciences reported net sales of 1,624.30 million and a net profit of -28.96 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 1,545.28 million, while total assets were reported at 4,037.42 million.

What does Integra LifeSciences Holdings Corp. do?

Integra LifeSciences Holdings Corp. specializes in regenerative technologies and neurosurgical solutions within the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of $383 million and a market cap of approximately $1 billion.

Overview: <BR>Integra LifeSciences Holdings Corp. provides regenerative technologies and neurosurgical solutions in the Pharmaceuticals & Biotechnology industry, operating within the small-cap market.<BR><BR>Financial Snapshot: <BR>Net Sales: 383 Million (Quarterly Results - Mar 2025) <BR>Net Profit: -25 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 1,003.73 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 10.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 1.04 <BR>Return on Equity: 7.03% <BR>Price to Book: 0.66<BR><BR>Contact Details: <BR>Address: 1100 CAMPUS ROAD, PRINCETON NJ: 08540 <BR>Tel: 1 609 2750500 <BR>Fax: 1 609 7504277 <BR>Website: https://www.integralife.com/

Should I buy, sell or hold Integra LifeSciences Holdings Corp.?

Who are in the management team of Integra LifeSciences Holdings Corp.?

As of March 2022, the management team of Integra LifeSciences Holdings Corp. includes Dr. Stuart Essig (Independent Chairman), Mr. Peter Arduini (CEO), and several independent directors: Ms. Barbara Hill, Ms. Rhonda Ballintyn, Dr. Keith Bradley, Mr. Lloyd Howell, and Dr. Donald Morel. They are responsible for the company's strategic direction and governance.

As of March 2022, the management team of Integra LifeSciences Holdings Corp. includes the following individuals:<BR><BR>- Dr. Stuart Essig: Independent Chairman of the Board<BR>- Mr. Peter Arduini: President, Chief Executive Officer, Director<BR>- Ms. Barbara Hill: Independent Presiding Director<BR>- Ms. Rhonda Ballintyn: Independent Director<BR>- Dr. Keith Bradley: Independent Director<BR>- Mr. Lloyd Howell: Independent Director<BR>- Dr. Donald Morel: Independent Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and governance.

Is Integra LifeSciences Holdings Corp. overvalued or undervalued?

As of November 4, 2024, Integra LifeSciences Holdings Corp. is considered overvalued and risky, with a P/E ratio of 10 and a year-to-date return of -32.19%, significantly underperforming its peers and the S&P 500.

As of 4 November 2024, the valuation grade for Integra LifeSciences Holdings Corp. has moved from expensive to risky. The company appears to be overvalued given its current metrics, including a P/E ratio of 10, a Price to Book Value of 0.73, and an EV to EBITDA of 9.20. In comparison, peers such as Globus Medical, Inc. have a P/E of 18.37 and Sanmina Corp. boasts a P/E of 39.80, indicating that Integra is lagging behind its competitors in terms of valuation.<BR><BR>Furthermore, Integra's recent stock performance has been disappointing, with a year-to-date return of -32.19%, significantly underperforming the S&P 500's return of 12.22% in the same period. This underperformance, coupled with the company's risky valuation grade, reinforces the conclusion that Integra LifeSciences is currently overvalued.

Is Integra LifeSciences Holdings Corp. technically bullish or bearish?

As of October 31, 2025, Integra LifeSciences Holdings Corp. shows a mildly bearish trend with key indicators like moving averages and Bollinger Bands supporting this view, despite a slightly bullish weekly MACD, and has underperformed the S&P 500 with a year-to-date return of -50.18%.

As of 31 October 2025, the technical trend for Integra LifeSciences Holdings Corp. has changed from sideways to mildly bearish. The current technical stance is bearish, with key indicators supporting this view including bearish signals from the daily moving averages and Bollinger Bands on both weekly and monthly timeframes. Although the weekly MACD is mildly bullish, the overall sentiment remains negative due to the lack of strong bullish signals from the RSI and Dow Theory, which indicate no trend. Additionally, the company's performance has significantly lagged behind the S&P 500, with a year-to-date return of -50.18% compared to the S&P 500's 16.30%.